Testing SER-155 for immunotherapy-related diarrhea
Part of Digestive system clinical trials.
This trial tests an investigational oral medication (SER-155) for people whose diarrhea is caused by immunotherapy. It aims to calm the gut and reduce symptoms without needing stronger drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have received immunotherapy (checkpoint inhibitor) in the last 6 months.
- You have moderate diarrhea (at least 4 more bowel movements per day than usual) that your doctor thinks is related to immunotherapy.
- You can swallow pills.
- You have not already been treated with high-dose steroids or special anti-inflammatory drugs for this diarrhea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
This trial tests whether a treatment called fecal microbiota transplant (FMT) — transferring healthy gut bacteria — can help relieve diarrhea and colitis caused by immunotherapy drugs. If you have melanoma or kidney cancer and are experiencing diarrhea after immunotherapy, this study may offer a new option.
This trial tests a new treatment, KAN-004, for people with diarrhea or colon inflammation caused by cancer immunotherapy. It aims to help manage these side effects.
This trial tests if ustekinumab can help cancer patients who have diarrhea or colitis caused by immune checkpoint inhibitors. It may be an option if standard treatments haven't worked or aren't suitable.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This trial tests if giving vedolizumab early can help control severe diarrhea and colon inflammation caused by immunotherapy (a type of cancer treatment). It may offer a new option for people who develop these side effects.
Hear when a new Diarrhea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.